Our take
NewIcon builds compounding robots that prepare intravenous antibiotic doses, plus automated dispensing systems for pharmacies and dispensing cabinets for hospital wards. Its compounding systems prepare up to 500,000 doses a year.2,3
It suits hospital pharmacies, mainly in the Nordics, that want to automate antibiotic preparation. Buyers should weigh its small size and weak balance sheet.5
Scores by criterion
Pricing transparency, 3.0: NewIcon publishes no prices for its systems.2
Product maturity, 6.5: It delivered its first automated dispensing system in 2008 and its first compounding system for intravenous antibiotics in 2015.3
Deployment evidence, 6.0: It has delivered systems in Finland, Denmark, Russia, Israel, Iran, and China, including what it calls the world's largest automated dispensing system at HUS Pharmacy in 2016.3
Company durability, 3.5: Revenue was 4.4 million euros in 2025, up 4.6 percent, with an operating margin of minus 10.9 percent and negative equity, according to Finnish credit records.5
Ease of integration, 6.0: The compounding systems are designed for hospital pharmacy clean rooms, and the cabinets and dispensing systems connect to the pharmacy's medication workflow.2,1
Each criterion is defined on our methodology page.
Who uses NewIcon and what it's for
The buyer is a hospital pharmacy that wants to automate the preparation of intravenous antibiotic doses or automate dispensing.2
Buyers should compare it with ARxIUM, EQUASHIELD Pro, KIRO Oncology, Omnicell, and Loccioni.
Compounding and dispensing
The IV ICON system prepares ready-to-administer intravenous antibiotic doses in hospital pharmacies. NewIcon also makes automated dispensing systems for pharmacies and dispensing cabinets for wards.2,1
Deployments
NewIcon entered Russia in 2012, Israel in 2015, Iran and China in 2016, and Denmark in 2017. In 2018 it set up a joint venture with a Shanghai health IT company.3
Pricing
NewIcon does not publish prices.2
Company, ownership, and revenue
Ossi Parviainen founded the company in 2007 and is chief executive officer. It raised 4.4 million euros in a crowdfunded share issue in 2017 and 4.5 million euros from Highlight Health Investment in 2018.3,4
Revenue was 4.4 million euros in 2025 with 37 employees.5
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where NewIcon wins or loses |
|---|---|---|---|---|
| NewIcon | IV ICON compounding for intravenous antibiotics, dispensing systems and cabinets2 | Not published2 | Hospitals and pharmacies in six countries, mainly Finland3 | Finnish IV compounding maker; small and loss-making |
| ARxIUM | RIVA IV robot plus packagers, cabinets, and inventory software6 | Not published; consultation16 | More than 19 million RIVA doses7 | ARxIUM wins on one vendor for IV robots and wider pharmacy automation. NewIcon wins on intravenous antibiotic compounding at a small vendor. |
| EQUASHIELD Pro | Automated hazardous drug compounder using closed transfer devices9 | Not published; quote9 | Equashield sells on five continents10 | EQUASHIELD wins on closed transfer protection from start to finish. NewIcon wins on intravenous antibiotic compounding at a small vendor. |
| KIRO Oncology | Two-arm hazardous drug compounder with gravimetric checks11 | Not published; quote11 | Part of the inclusiv IV compounding portfolio17 | KIRO wins on gravimetric checks and self-cleaning. NewIcon wins on intravenous antibiotic compounding at a small vendor. |
| Omnicell | IVX Station robot inside the IV Compounding Service14 | Not published; service model14 | Hospitals, clinics, and care settings13 | Omnicell wins on a managed IV compounding service. NewIcon wins on intravenous antibiotic compounding at a small vendor. |
| Loccioni APOTECAchemo | APOTECAchemo IV chemotherapy compounding robot15 | Not published15 | User community across the US, Europe, the Gulf, and Asia15 | Loccioni wins on an established chemo compounding user community. NewIcon wins on intravenous antibiotic compounding at a small vendor. |
Limits
Operating losses and negative equity.5
No published prices.2
Small team of 37 people.5
What customers say
Where it helps
Automated intravenous antibiotic compounding for hospital pharmacies.2
Where it falls short
Weak balance sheet.5
Leadership

Ossi Parviainen
Founder and CEOOssi Parviainen founded NewIcon in 2007 and is its chief executive officer.3,4
Sources
- NewIcon, homepage, accessed November 12, 2026
- NewIcon, Compounding system, accessed November 12, 2026
- NewIcon, CEO's greetings and milestones, accessed November 12, 2026
- NewIcon, Management, accessed November 12, 2026
- Luottoriskit.fi, NewIcon Oy financial statements, accessed November 12, 2026
- ARxIUM, RIVA robotic IV automation and compounding systems, accessed November 10, 2026
- ARxIUM, News and events hub, accessed November 10, 2026
- ARxIUM, Our headquarters, accessed November 10, 2026
- Equashield, EQUASHIELD Pro automated compounding of hazardous drugs, accessed November 10, 2026
- Nordic Capital, Equashield portfolio company profile, accessed November 10, 2026
- Kiro Grifols, KIRO Oncology, accessed November 10, 2026
- Grifols, Grifols reports revenues of EUR 7,524m, up 7% (February 26, 2026), accessed November 10, 2026
- Omnicell, homepage, accessed November 10, 2026
- Omnicell, IV compounding, accessed November 10, 2026
- Loccioni, Apoteca Community, accessed November 10, 2026
- ARxIUM, homepage, accessed November 10, 2026
- Kiro Grifols, Robotic and other compounding devices, accessed November 10, 2026
- Omnicell, Fiscal year and fourth quarter 2025 financial results, accessed November 16, 2026

